Insmed Inc (INSM)vsJanux Therapeutics Inc (JANX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
JANX
Janux Therapeutics Inc
$13.56
-2.45%
HEALTHCARE · Cap: $824.88M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 5964% more annual revenue ($606.42M vs $10.00M). JANX leads profitability with a 0.0% profit margin vs -2.1%. JANX earns a higher WallStSmart Score of 40/100 (D).
INSM
Hold39
out of 100
Grade: F
JANX
Hold40
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 21.8% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : JANX
The strongest argument for JANX centers on Price/Book, Debt/Equity, Altman Z-Score. Revenue growth of 21.8% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : JANX
The primary concerns for JANX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while JANX is a growth play — different risk/reward profiles.
JANX carries more volatility with a beta of 2.88 — expect wider price swings.
JANX is growing revenue faster at 21.8% — sustainability is the question.
JANX generates stronger free cash flow (-29M), providing more financial flexibility.
Bottom Line
JANX scores higher overall (40/100 vs 39/100) and 21.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Janux Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?